If you live with Parkinson’s, you’ve probably seen headlines promising the next big breakthrough.
Sometimes those stories fade.
Sometimes progress is real, but quieter, slower, and harder earned.
Right now, two very different Parkinson’s therapies are entering the final stage of clinical testing. They take separate paths, but together they signal meaningful forward movement, not a cure, but real progress.
A Near-Term Option for Symptom Control
Drug name: Tavapadon
Tavapadon is a once-daily oral medication designed to help manage common Parkinson’s motor symptoms such as stiffness, tremor, and slowness of movement.
In late 2025, the biopharmaceutical company AbbVie submitted a New Drug Application (NDA) to the U.S. Food and Drug Administration seeking approval for Tavapadon following positive Phase 3 clinical trial results. FDA review of an NDA typically takes about 10 months, after which the drug may be approved for use.
What makes Tavapadon different is how it works. Many existing Dopamine Agonists primarily target D2 and D3 Dopamine receptors and can sometimes cause side effects such as excessive daytime sleepiness, compulsive behaviors, or psychosis. Tavapadon instead acts as a partial agonist at D1 and D5 Dopamine receptors, and this different binding profile appears to result in fewer side effects overall.
In clinical studies, people taking Tavapadon experienced:
- Meaningful improvements in motor symptoms and daily function
- More consistent symptom control throughout the day
- About one additional hour of “ON” time per day when used alongside levodopa, without troublesome side effects
If approved, Tavapadon could become a valuable near-term option that smooths motor symptoms and may reduce the need for more frequent Levodopa dosing.
A Longer-Term, Regenerative Approach
The second therapy takes a much bolder approach.
Bemdaneprocel is a stem cell–based treatment designed to replace the Dopamine-producing brain cells that are lost in Parkinson’s. These lab-grown cells are implanted directly into the area of the brain affected by the disease, with the goal of restoring dopamine production more naturally.
Earlier, smaller studies showed that the procedure could be performed safely and that the transplanted cells survived and appeared to integrate into the brain. Based on those results, the therapy has now entered a large global Phase 3 clinical trial, the first of its kind for Parkinson’s.
This approach is still experimental, involves brain surgery, and will take years to fully evaluate. But if successful, Bemdaneprocel could represent the first Parkinson’s therapy aimed at repairing underlying damage, rather than only managing symptoms.
Why These Developments Matter
Together, these therapies show Parkinson’s research moving forward on two important fronts:
- Improving quality of life now, with better symptom control and fewer side effects
- Pursuing long-term restorative solutions that aim to replace what the disease takes away
Neither therapy has a guaranteed path to approval. Late-stage trials must still confirm safety, durability, and real-world benefit. But reaching Phase 3, especially with two such different approaches, represents genuine momentum in the field.
Progress in Parkinson’s is often incremental.
Incremental progress still changes lives.
Key Takeaways
- A new Parkinson’s medication, Tavapadon, is under FDA review for potential approval
- A first-of-its-kind stem cell therapy, Bemdaneprocel, is being tested in a large Phase 3 trial
- Neither is a cure, but both expand future treatment options
- More options mean more personalized care and better symptom management over time
We’ continue to track these developments and translate what they mean: clearly, calmly, and without hype.
